Dr Farago speaks with ecancer at AACR 2017 about results from a phase I/II study of treating patients with small cell lung cancer (SCLC) following relapsed after chemotherapy. She describes the rationale of adding olaparib, a PARP inhibitor preventing...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2plO6ll
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Be a Responsible Dog Owner . Among companion animals, dogs are unmatched in their devotion, loyalty and friendship to humankind. Anyone who ...
-
is the premiere name in online OSHA Outreach training and safety courses. Our interactive courses include 10 hour and 30 hour OSHA Outreach,...
-
Masters Thesis Proposal Outline INTRODUCTION (1 PAGE) • What is the general topic area • Why this topic is relevant/important (how important...
-
Abstract We present a case of small coronary sinus defect detected after transcatheter device closure of a large secundum atrial septal de...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
An examination of the etiologic overlap between the genetic and environmental influences on insomnia and common psychopathology. Depre...
-
Publication date: Available online 5 April 2017 Source: European Annals of Otorhinolaryngology, Head and Neck Diseases Author(s): C.A. Ri...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGJfK4 via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου